Reuters logo
Shire's angioedema drug succeeds in late-stage study
May 18, 2017 / 11:12 AM / 6 months ago

Shire's angioedema drug succeeds in late-stage study

May 18 (Reuters) - Shire Plc said on Thursday its drug for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling, was successful in a late-stage study.

The drug, lanadelumab, is being developed to prevent angioedema attacks. It was tested against a placebo over 26 weeks in patients 12 years of age or older with the rare genetic disease. (Reporting by Natalie Grover in Bengaluru; Editing by Martina D‘Couto)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below